During the past decade, Boise Kidney and Hypertension Institute conducted 17 clinical trials. In the 10-year time frame, 17 clinical trials started and 8 clinical trials were completed, i.e. on average, 47.1% percent of trials that started reached the finish line to date. In the past 5 years, 11 clinical trials started and 5 clinical trials were completed. i.e. 45.5% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Boise Kidney and Hypertension Institute" #1 sponsor was "Boehringer Ingelheim" with 4 trials, followed by "Reata Pharmaceuticals, Inc." with 4 trials sponsored, "Pfizer" with 3 trials sponsored, "Prokidney" with 3 trials sponsored and "Novartis" with 3 trials sponsored. Other sponsors include 5 different institutions and companies that sponsored additional 15 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Boise Kidney and Hypertension Institute" #1 collaborator was "CTI Clinical Trial and Consulting Services" with 2 trials as a collaborator, "Bristol-Myers Squibb" with 1 trials as a collaborator, "Eli Lilly and Company" with 1 trials as a collaborator and "Hospira, now a wholly owned subsidiary of Pfizer" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 4 trials.

According to Clinical.Site data, the most researched conditions in "Boise Kidney and Hypertension Institute" are "Chronic Kidney Disease" (6 trials), "Autosomal Dominant Polycystic Kidney" (3 trials), "Diabetes Mellitus, Type 2" (3 trials), "Diabetic Nephropathies" (3 trials) and "ADPKD" (2 trials). Many other conditions were trialed in "Boise Kidney and Hypertension Institute" in a lesser frequency.

Most popular intervention types in "Boise Kidney and Hypertension Institute" are "Drug" (22 trials) and "Biological" (4 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (9 trials), "Renal Autologous Cell Therapy (REACT)" (3 trials), "BI 685509" (2 trials), "vildagliptin" (2 trials) and "BI 690517" (1 trials). Other intervention names were less common.

The vast majority of trials in "Boise Kidney and Hypertension Institute" are 26 trials for "All" genders.

Currently, there are NaN active trials in "Boise Kidney and Hypertension Institute". undefined are not yet recruiting, 6 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 16 completed trials in Boise Kidney and Hypertension Institute, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Boise Kidney and Hypertension Institute, 4 "Phase 1" clinical trials were conducted, 13 "Phase 2" clinical trials and 9 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".